
Marcelo M S Lima

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2204170/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1104-1114.	2.5	201
2	Anxiety in Parkinson's disease: A critical review of experimental and clinical studies. Neuropharmacology, 2012, 62, 115-124.	2.0	167
3	Chronic ï‰-3 fatty acids supplementation promotes beneficial effects on anxiety, cognitive and depressive-like behaviors in rats subjected to a restraint stress protocol. Behavioural Brain Research, 2011, 219, 116-122.	1.2	142
4	The role of 5-HT1A receptors in fish oil-mediated increased BDNF expression in the rat hippocampus and cortex: A possible antidepressant mechanism. Neuropharmacology, 2012, 62, 184-191.	2.0	108
5	The Role of the Substantia Nigra Pars Compacta in Regulating Sleep Patterns in Rats. PLoS ONE, 2007, 2, e513.	1.1	90
6	Sleep disturbances in Parkinson's disease: The contribution of dopamine in REM sleep regulation. Sleep Medicine Reviews, 2013, 17, 367-375.	3.8	89
7	PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 53, 35-44.	2.5	86
8	Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behavioural Brain Research, 2014, 274, 390-399.	1.2	75
9	Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Research, 2006, 1101, 117-125.	1.1	74
10	Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin. Behavioural Brain Research, 2014, 259, 70-77.	1.2	62
11	Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats. Brain Research, 2014, 1593, 95-105.	1.1	62
12	Modulation of sickness behavior by sleep: The role of neurochemical and neuroinflammatory pathways in mice. European Neuropsychopharmacology, 2009, 19, 589-602.	0.3	58
13	Blockage of dopaminergic D2 receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation. Behavioural Brain Research, 2008, 188, 406-411.	1.2	56
14	ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease. Molecular Neurobiology, 2017, 54, 5798-5806.	1.9	54
15	Does Parkinson's Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?. CNS and Neurological Disorders - Drug Targets, 2014, 13, 418-428.	0.8	50
16	Fish oil improves anxietyâ€like, depressiveâ€like and cognitive behaviors in olfactory bulbectomised rats. European Journal of Neuroscience, 2014, 39, 266-274.	1.2	48
17	The Pronociceptive Effect of Paradoxical Sleep Deprivation in Rats: Evidence for a Role of Descending Pain Modulation Mechanisms. Molecular Neurobiology, 2016, 53, 1706-1717.	1.9	46
18	Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone administration. Pharmacological Reports, 2012, 64, 1081-1090.	1.5	42

MARCELO M S LIMA

#	Article	IF	CITATIONS
19	Behavioral, Neurochemical and Histological Alterations Promoted by Bilateral Intranigral Rotenone Administration: A New Approach for an Old Neurotoxin. Neurotoxicity Research, 2012, 21, 291-301.	1.3	36
20	REM sleep deprivation generates cognitive and neurochemical disruptions in the intranigral rotenone model of Parkinson's disease. Journal of Neuroscience Research, 2013, 91, 1508-1516.	1.3	36
21	Olfactory impairment in the rotenone model of Parkinsonââ,¬â"¢s disease is associated with bulbar dopaminergic D2 activity after REM sleep deprivation. Frontiers in Cellular Neuroscience, 2014, 8, 383.	1.8	36
22	Repeated intranigral MPTP administration: A new protocol of prolonged locomotor impairment mimicking Parkinson's disease. Journal of Neuroscience Methods, 2008, 167, 268-277.	1.3	31
23	Maternal Omega-3 Supplement Improves Dopaminergic System in Pre- and Postnatal Inflammation-Induced Neurotoxicity in Parkinson's Disease Model. Molecular Neurobiology, 2017, 54, 2090-2106.	1.9	31
24	Intermittent hypoxia and sleep restriction: Motor, cognitive and neurochemical alterations in rats. Behavioural Brain Research, 2008, 189, 373-380.	1.2	29
25	Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behavioural Brain Research, 2011, 216, 186-192.	1.2	29
26	Neonatal exposure to constant light prevents anhedonia-like behavior induced by constant light exposure in adulthood. Behavioural Brain Research, 2011, 222, 10-14.	1.2	28
27	The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease. Neuroscience, 2015, 300, 246-253.	1.1	28
28	Intranigral LPS Administration Produces Dopamine, Glutathione but not Behavioral Impairment in Comparison to MPTP and 6-OHDA Neurotoxin Models of Parkinson's Disease. Neurochemical Research, 2010, 35, 1620-1627.	1.6	25
29	Ascending Nociceptive Control Contributes to the Antinociceptive Effect of Acupuncture in a Rat Model of Acute Pain. Journal of Pain, 2014, 15, 422-434.	0.7	25
30	REM Sleep Deprivation Reverses Neurochemical and Other Depressive-Like Alterations Induced by Olfactory Bulbectomy. Molecular Neurobiology, 2015, 51, 349-360.	1.9	25
31	Chronic sleep restriction increases pain sensitivity over time in a periaqueductal gray and nucleus accumbens dependent manner. Neuropharmacology, 2018, 139, 52-60.	2.0	24
32	Putative role of monoamines in the antidepressant-like mechanism induced by striatal MT2 blockade. Behavioural Brain Research, 2014, 275, 136-145.	1.2	22
33	Unraveling a new circuitry for sleep regulation in Parkinson's disease. Neuropharmacology, 2016, 108, 161-171.	2.0	21
34	Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson's Disease. Molecular Neurobiology, 2019, 56, 1082-1095.	1.9	21
35	Antidepressant-like effect of celecoxib piroxicam in rat models of depression. Journal of Neural Transmission, 2014, 121, 671-82.	1.4	20
36	Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation. Neuropharmacology, 2014, 76, 118-126.	2.0	20

MARCELO M S LIMA

#	Article	IF	CITATIONS
37	The Antidepressant-Like Effect of Fish Oil: Possible Role of Ventral Hippocampal 5-HT1A Post-synaptic Receptor. Molecular Neurobiology, 2015, 52, 206-215.	1.9	19
38	REM sleep deprivation and dopaminergic D2 receptors modulation increase recognition memory in an	1.2	19
39	Dopaminergic mechanisms in periaqueductal gray-mediated antinociception. Behavioural Pharmacology, 2018, 29, 225-233.	0.8	18
40	Chronic sleep restriction in the rotenone Parkinson's disease model in rats reveals peripheral early-phase biomarkers. Scientific Reports, 2019, 9, 1898.	1.6	17
41	REM sleep deprivation promotes a dopaminergic influence in the striatal MT2 anxiolytic-like effects. Sleep Science, 2016, 9, 47-54.	0.4	11
42	The dopaminergic dilema: Sleep or wake? Implications in Parkinson's disease. Bioscience Hypotheses, 2008, 1, 9-13.	0.2	9
43	Disruption of neocortical synchronisation during slowâ€wave sleep in the rotenone model of Parkinson's disease. Journal of Sleep Research, 2021, 30, e13170.	1.7	7
44	Olfactory impairment is related to REM sleep deprivation in rotenone model of Parkinson's disease. Sleep Science, 2017, 10, 47-54.	0.4	7
45	The mechanism of antidepressant-like effects of piroxicam in rats. Journal of Pharmacology and Pharmacotherapeutics, 2015, 6, 7-12.	0.2	5
46	Cholinergic Oculomotor Nucleus Activity Is Induced by REM Sleep Deprivation Negatively Impacting on Cognition. Molecular Neurobiology, 2017, 54, 5721-5729.	1.9	5
47	Perspectives for the association between olfactory disturbances and depression in Parkinson's disease. Neural Regeneration Research, 2019, 14, 591.	1.6	5
48	Medicinal Plants in Management of Type 2 Diabetes and Neurodegenerative Disorders. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-2.	0.5	3
49	A circuitry for sleep in Parkinson's disease. Oncotarget, 2017, 8, 5654-5655.	0.8	2